109 related articles for article (PubMed ID: 12704865)
21. Pharmacokinetics and pharmacodynamics of terguride following intramuscular administration in cows and goats.
Lapka R; Krejci P; Lidický J; Frühaufová M; Rezábek K
Acta Physiol Pol; 1989; 40(1):139-44. PubMed ID: 2603744
[TBL] [Abstract][Full Text] [Related]
22. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
Akai T; Yamaguchi M; Mizuta E; Kuno S
Ann Neurol; 1993 May; 33(5):507-11. PubMed ID: 8098931
[TBL] [Abstract][Full Text] [Related]
23. Discriminative stimulus effects of cocaine in squirrel monkeys: lack of antagonism by the dopamine D2 partial agonists terguride, SDZ 208-911, and SDZ 208-912.
Spealman RD
Pharmacol Biochem Behav; 1995 Aug; 51(4):661-5. PubMed ID: 7675840
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and endocrine effects of terguride in healthy subjects.
Krause W; Träger H; Kühne G; Sauerbrey N; Gräf KJ; Dorow R
Eur J Clin Pharmacol; 1990; 38(6):609-15. PubMed ID: 2373136
[TBL] [Abstract][Full Text] [Related]
25. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride.
Dallabonzana D; Liuzzi A; Oppizzi G; Cozzi R; Verde G; Chiodini P; Rainer E; Dorow R; Horowski R
J Clin Endocrinol Metab; 1986 Oct; 63(4):1002-7. PubMed ID: 3745401
[TBL] [Abstract][Full Text] [Related]
26. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
Peacock L; Gerlach J
Eur J Pharmacol; 1993 Jun; 237(2-3):329-40. PubMed ID: 8103465
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of the dopamine partial agonist, terguride, in the rat and rhesus monkey.
Krause W; Hümpel M
Eur J Drug Metab Pharmacokinet; 1988; 13(3):185-94. PubMed ID: 3240764
[TBL] [Abstract][Full Text] [Related]
28. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat.
Pulvirenti L; Balducci C; Piercy M; Koob GF
J Pharmacol Exp Ther; 1998 Sep; 286(3):1231-8. PubMed ID: 9732383
[TBL] [Abstract][Full Text] [Related]
30. Pre- and postsynaptic actions of a partial D2 receptor agonist in reserpinized young rats: longevity of agonistic effects.
Farley CM; Baella SA; Wacan JJ; Crawford CA; McDougall SA
Brain Res; 2006 Dec; 1124(1):37-44. PubMed ID: 17070785
[TBL] [Abstract][Full Text] [Related]
31. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
[TBL] [Abstract][Full Text] [Related]
32. Suppression of puerperal lactation by terguride. A double-blind study.
Venturini PL; Horowski R; Fasce V; Valenzano M; Ferreri C; Badino G; Rainer E; Scholz A; De Cecco L
Gynecol Obstet Invest; 1988; 26(1):33-8. PubMed ID: 3049266
[TBL] [Abstract][Full Text] [Related]
33. [Effects of the partial dopamine receptor agonist, terguride, on the field-stimulated vas deferens in the mouse].
Carratù MR; De Serio A; Lagioia R; Conte-Camerino D; Ferrari E; Mitolo-Chieppa D
Boll Soc Ital Biol Sper; 1990 Jan; 66(1):35-42. PubMed ID: 1969741
[TBL] [Abstract][Full Text] [Related]
34. Unusual interactions between the neuroleptic haloperidol, and the dopamine D2 partial agonist, terguride.
Stephens DN; Löschmann PA; Lanzinger C; Wachtel H; Montgomery AM; Herberg LJ
Behav Pharmacol; 1990; 1(6):521-529. PubMed ID: 11175438
[TBL] [Abstract][Full Text] [Related]
35. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
Tadori Y; Miwa T; Tottori K; Burris KD; Stark A; Mori T; Kikuchi T
Eur J Pharmacol; 2005 May; 515(1-3):10-9. PubMed ID: 15894311
[TBL] [Abstract][Full Text] [Related]
36. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
Tsuboi T; Bies RR; Suzuki T; Mamo DC; Pollock BG; Graff-Guerrero A; Mimura M; Uchida H
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():178-82. PubMed ID: 23727135
[TBL] [Abstract][Full Text] [Related]
37. Dopamine receptor and adrenoceptor agonists inhibit prolactin release from MMQ cells.
Judd AM; MacLeod RM
Eur J Pharmacol; 1991 Mar; 195(1):101-6. PubMed ID: 1676676
[TBL] [Abstract][Full Text] [Related]
38. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat.
Yonezawa K; Tamaki N; Kokunai T
Neurol Med Chir (Tokyo); 1997 Dec; 37(12):901-6. PubMed ID: 9465588
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
40. Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease.
Koller WC; Herbster G
Neurology; 1987 Apr; 37(4):723-7. PubMed ID: 3561789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
